
The WTC adjuvant pipeline has been successfully tested in different R&D models such as OVA, as well as for various indications. WTC adjuvants have been tested in various species, through an internal R&D program or private and public collaboration.
Results so far have confirmed NKT activity in vivo in mice and non human primates. In vitro/ex vivo in human neonates, adults and elderly also confirm such effect.
In addition, the effects of the adjuvant in mice and primates have been well demonstrated in several models.
